GSK plc Overview
Valuation check: GLAXF's ROE is 86.8%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow86.80%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
GSK plc (GLAXF) currently reports a ROE of 86.8%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore GSK plc's ROE history and peer comparisons.
GSK plc's ROE of 86.8% is higher than the Healthcare sector average of 11.15%. That is roughly 678.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but GSK plc's current 86.8% should be judged against Healthcare norms (sector average: 11.15%) and against GLAXF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 86.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for GSK plc, and consider following GLAXF for alerts when major investors trade the stock.
GSK plc is classified in the Healthcare sector. On ROE, it currently shows 86.8% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLAXF with unrelated industries.
